Inventor · disambiguated record
Simon Green
Also filed as: GREEN SIMON · GREEN SIMON R · GREEN SIMON RICHARD
18 granted patents·19 pending applications·99 citations·filing 1986–2023
91Inventor score
Files withCYCLACEL LTD13JANSSEN PHARMACEUTICA NV5INT RECTIFIER CORP2BOSCH GMBH ROBERT1CEBON JONATHAN1
Top patents by PatentIndex Score
37 records- 0189US7026278B2Rinse-added fabric treatment composition, kit containing such, and method of use thereforPROCTER & GAMBLE·Filed 2001·Granted Apr 11, 2006·39 cites·18 claims
- 0287US8975239B2Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaineCYCLACEL LTD·Filed 2013·Granted Mar 10, 2015·16 cites·15 claims
- 0384US8349792B2Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agentCYCLACEL LTD·Filed 2007·Granted Jan 8, 2013·3 cites·14 claims
- 0474US9173938B2Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disordersGREEN SIMON·Filed 2009·Granted Nov 3, 2015·1 cites·19 claims
- 0572US8592581B2Trisubstituted purine derivativesSHELDRAKE PETER WILLIAM·Filed 2009·Granted Nov 26, 2013·4 cites·32 claims
- 0672US6852906B2Assay for measuring enzyme activity in vivoCYCLACEL LTD·Filed 2002·Granted Feb 8, 2005·13 cites·19 claims
- 0771US8530445B2Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaineGREEN SIMON RICHARD·Filed 2009·Granted Sep 10, 2013·3 cites·40 claims
- 0869US7772207B2Combination of a CDK inhibitor and CS-682 or a metabolite thereofCYCLACEL LTD·Filed 2004·Granted Aug 10, 2010·9 cites·5 claims
- 0962USD298526SSteering wheelGREEN SIMON R·Filed 1986·Granted Nov 15, 1988·11 cites·1 claims
- 1059US11186589B2Cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 30, 2021·0 cites·20 claims
- 1157US2025129084A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2023·Application pending·0 cites
- 1254US2009306230A1High Throughput Testing for Presence of Microorganisms in a Biological SampleSTIRUS GLOBAL SOLUTIONS LTD·Filed 2007·Application pending·0 cites
- 1353US2019119299A1Cyanoindoline derivatives as nik inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Application pending·0 cites
- 1450US2006075576A1Rinse-added fabric treatment composition, kit containing such, and method of use thereforPRICE KENNETH N·Filed 2005·Application pending·0 cites
- 1550US2016108467A1High throughput testing for presence of microorganisms in a biological sampleROCHESTER INVEST PARTNERS·Filed 2015·Application pending·0 cites
- 1649US9872874B2Dosage regimen for sapacitabine and seliciclibCYCLACEL LTD·Filed 2013·Granted Jan 23, 2018·0 cites·11 claims
- 1749US2005164976A1Combination of a cdk inhibitor and 5-fu for the tratment of cancerCYCLACEL LTD·Filed 2003·Application pending·0 cites
- 1848US2010304361A1Method and device for monitoring a therapeutic treatment regimeDAS DEV PARTNERS·Filed 2008·Application pending·0 cites
- 1947US2007190072A1In vivo efficacy of ny-eso-1 plus adjuvantCSL LTD LUDWIG INST FOR CANCER·Filed 2004·Application pending·0 cites
- 2047US2013005747A1Method for selecting a cancer therapyCYCLACEL LTD·Filed 2011·Application pending·0 cites
- 2147US2013196938A1Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agentCYCLACEL LTD·Filed 2012·Application pending·0 cites
- 2245US2006204975A1Markers for cyclin dependent kinase inhibitorsCYCLACEL LTD·Filed 2005·Application pending·0 cites
- 2343US2005153991A1Methods of treatment of chronic lymphocytic leukemia using roscovitineCYCLACEL LTD·Filed 2004·Application pending·0 cites
- 2442US12147826B2Extending a software defined network between public cloud computing architecture and a data centerJUNIPER NETWORKS INC·Filed 2021·Granted Nov 19, 2024·0 cites·18 claims
- 2542US9041224B2Method for producing a solder jointBOSCH GMBH ROBERT·Filed 2012·Granted May 26, 2015·0 cites·11 claims
- 2642US2009274773A1Antiproliferative combination comprising cyc-682 and a cytotoxic agentCYCLACEL LTD·Filed 2006·Application pending·0 cites
- 2742US2006188898A1Markers for roscovitineCYCLACEL LTD·Filed 2005·Application pending·0 cites
- 2840US7602015B2Process to control semiconductor wafer yieldINT RECTIFIER CORP·Filed 2006·Granted Oct 13, 2009·0 cites·12 claims
- 2940US7385273B2Power semiconductor deviceINT RECTIFIER CORP·Filed 2006·Granted Jun 10, 2008·0 cites·9 claims
- 3040US2014176548A1Facial image enhancement for video communicationNVIDIA CORP·Filed 2012·Application pending·0 cites
- 3140US2009306098A1Combination of roscovitine and a hdca inhibitor to treat proliferative diseasesCYCLACEL LTD·Filed 2006·Application pending·0 cites
- 3239US11180487B2Substituted cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Nov 23, 2021·0 cites·15 claims
- 3339US11136311B2Heteroaromatic derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Oct 5, 2021·0 cites·15 claims
- 3439US11001569B26-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted May 11, 2021·0 cites·8 claims
- 3537US2012171232A1In vivo efficacy of ny-eso-1 plus adjuvantCEBON JONATHAN·Filed 2011·Application pending·0 cites
- 3635US2016000894A1In vivo efficacy of ny-eso-1 plus adjuvantCSL LTD·Filed 2015·Application pending·0 cites
- 3724US2002018774A1CANDIDA ALBICANS mRNA 5'5-TRIPHOSPHATASE (CET-1) POLYNUCLEOTIDESFiled 1998·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Simon Green files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →